7,608.50

+11.75

+0.15%

52,168.00

+273.00

+0.53%

28,313.00

+7.25

+0.03%

Russell 2000 Futures

2,843.90

+18.90

+0.67%

4.9520

+0.0580

+1.19%

19.13

-1.70

-8.17%

4,044.50

+104.10

+2.64%

78,330.92

+1,384.31

+1.80%

Crude Oil Dec 26

96.38

+0.29

+0.30%

US Private Equity

10,855.23

+18.94

+0.17%

Swiss - Delayed Quote CHF

Roche Holding AG (RO.SW)

398.40 -0.60 (-0.15%)

As of 9:56:22 AM GMT+1. Market Open.

Loading Chart for RO.SW

Chart Range Bar

Interval:

In partnership with ChartIQ

Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal

Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal

NRIX Slumps 35% After-Hours — What’s Driving The Selloff?

NRIX Slumps 35% After-Hours — What’s Driving The Selloff?

Madrigal Pharmaceuticals Inc (MDGL) Q3 2026 Earnings Call Highlights: First Profitable Quarter ...

Madrigal Pharmaceuticals Inc (MDGL) Q3 2026 Earnings Call Highlights: First Profitable Quarter ...

Biophotonics - Global Strategic Business Report 2026: Secure Share of a US$130.6 Billion Market by 2032, Led by Roche, GE Healthcare, Horiba, and IPG Photonics

Biophotonics - Global Strategic Business Report 2026: Secure Share of a US$130.6 Billion Market by 2032, Led by Roche, GE Healthcare, Horiba, and IPG Photonics

Roche Secures FDA Clearance for New cobas eplex Respiratory Panel Detecting Up to 19 Pathogens

Roche Secures FDA Clearance for New cobas eplex Respiratory Panel Detecting Up to 19 Pathogens

RNA Targeting Small Molecule Drug Discovery Market - Global Strategic Business Report: Secure a US$5.3B Market by 2030 as Amgen, AstraZeneca, Roche and Merck Accelerate RNA Pipelines

RNA Targeting Small Molecule Drug Discovery Market - Global Strategic Business Report: Secure a US$5.3B Market by 2030 as Amgen, AstraZeneca, Roche and Merck Accelerate RNA Pipelines

SIG vs. CFRUY: Which Stock Is the Better Value Option?

SIG vs. CFRUY: Which Stock Is the Better Value Option?

Biotechnology Reagents - Global Strategic Business Report: Capture the US$60.7 Billion Market by 2032 as Thermo Fisher, Roche, Danaher, Merck, and Bio-Rad Drive Disruption

Biotechnology Reagents - Global Strategic Business Report: Capture the US$60.7 Billion Market by 2032 as Thermo Fisher, Roche, Danaher, Merck, and Bio-Rad Drive Disruption

Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs

Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs

UBS sees Roche giredestrant potential priced in after 50% share rally

UBS sees Roche giredestrant potential priced in after 50% share rally

FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight

FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight

Mobilize your Website

View Site in Mobile | Classic

Share by: